Daniel Hill, MD
Family Medicine · Stillwater, OKNPI 1659358711
Payments from drug & device makers
Across 224 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$625
- Lilly USA, LLC$494
- Pfizer$365
- Amarin Pharma, Inc.$248
- Amgen$228
- Boehringer Ingelheim$221
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,771100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $625 |
| Lilly USA, LLC | 33 | $494 |
| Pfizer | 33 | $365 |
| Amarin Pharma, Inc. | 17 | $248 |
| Amgen | 9 | $228 |
| Boehringer Ingelheim | 18 | $221 |
| AbbVie | 9 | $204 |
| GSK | 11 | $174 |
| Novartis | 7 | $142 |
| Abbott | 9 | $139 |
| Sumitomo Pharma America, Inc. | 4 | $94 |
| Merck | 6 | $88 |
| Mylan Specialty L.p. | 4 | $85 |
| Novo Nordisk | 5 | $80 |
| Astellas Pharma US Inc | 4 | $52 |
| Ferring Pharmaceuticals Inc. | 3 | $52 |
| Johnson & Johnson | 4 | $49 |
| Exact Sciences | 3 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Dexcom, Inc. | 2 | $36 |
| Seqirus USA Inc | 1 | $31 |
| Harmony Biosciences LLC | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Bayer | 2 | $26 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Vertex | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Corium, LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Hologic Sales And Service, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,776 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 66 | $83,140 |
| OzempicSemaglutide | 75 | $76,789 |
| EliquisApixaban | 49 | $47,933 |
| JanuviaSitagliptin Phosphate | 43 | $39,764 |
| XifaxanRifaximin | 12 | $37,139 |
| FarxigaDapagliflozin Propanediol | 24 | $33,251 |
| MounjaroTirzepatide | 18 | $21,397 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $20,422 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $15,447 |
| XareltoRivaroxaban | 16 | $14,931 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $13,081 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $13,065 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $11,734 |
| TrulicityDulaglutide | 12 | $11,183 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $10,666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $221 | $83,14066 claims |
| Novo NordiskOzempic | $80 | $76,78975 claims |
| PfizerEliquis | $365 | $47,93349 claims |
| MerckJanuvia | $88 | $39,76443 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $14 | $37,13912 claims |
| AstraZenecaFarxiga, Symbicort | $625 | $36,92037 claims |
| Lilly USA, LLCMounjaro, Trulicity | $494 | $32,58130 claims |
| GSKTrelegy Ellipta | $174 | $15,44723 claims |
| Johnson & JohnsonXarelto | $49 | $14,93116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Stillwater
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.